glofitamab,brexucabtagene autoleucel,obinutuzumab,tocilizumab
gilead,roche
['brexu-cel', 'glofitamab', 'lymsm']
q: "how would you sequence brexu-cel and glofitamab in mcl if both are available?" makes the points that although bispecific follow-up data is only early, its off-the-shelf nature is promising compared to logistical challenges of car-t #tcellrx #ash22 #lymsm
haematology registrar | fellow @PORTAL_research @harvardmed |
evidence-based medicine | health policy | lymphoma | myeloma |
Fulbright scholar | muso | writer